Tags: Drug.

Temsirolimus (CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC) developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in late May 2007 and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.

Temsirolimus2DACS.svg
ATC prefix
L01
ATC suffix
XE09
CAS number
162635-04-3
DrugBank
DB06287
FDA UNII code
624KN6GM2T
IUPAC name
(1R2R4S)-4-(2R)-2-[(3S6R7E9R10R12R14S15E17E19E21S23S26R27R34aS)-927-dihydroxy-1021-dimethoxy-6812142026-hexamethyl-15112829-pentaoxo-1456910111213142122232425262728293132333434a-tetracosahydro-3H-2327-epoxypyrido[21-c][14]oxazacyclohentriacontin-3-yl]propyl-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
PubChem
6918289

Loading...

This page contains content from the copyrighted Wikipedia article "Temsirolimus"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.